ANNAPOLIS, Maryland, 28 août 2024 /PRNewswire/ — Alphyn Biologics, Inc, une société de dermatologie en phase clinique qui développe les Multi-Target Therapeutics®, annonce ce jour que les données de son essai clinique humain de phase 2a sur l’hydrogel de zabalafine (AB-101a) dans la…

NEW YORK, Aug. 27, 2024 /PRNewswire/ — Why: Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of all purchasers of securities of STMicroelectronics N.V (NYSE: STM) between January 25, 2024 and July 24, 2024. ST describes itself…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.